Baxalta Gmbh

Baxter International Inc.

Baxter Healthcare Sa

Nektar Therapeutics

Immuno Aktiengesellschaft

Baxter Aktiengesellschaft

Baxter Healthcare Inc.

Baxter Innovations Gmbh

Katalin Varadi

Peter Turecek

Hans-Peter Schwarz

Juergen Siekmann

Hanspeter Rottensteiner

Herbert Gritsch

Jutta Schreiner

Zhihao Fang

Mary J Bossard

Ping Zhang

Harold Zappe

Friedrich Scheiflinger

Alfred Weber

Hans Peter Schwarz

Gayle Stephenson

Stacy Mitchell

Hendrik Coenraad Hemker

Susanne Vejda

Suzette Lucette Beguin

Johann J Eibl

Sean M Culbertson

Heinz Anderle

Hartmut Lang

Berta Moritz

Sylvia Peyrer-Heimstaett

Brigitte Keil

Gerald Schrenk

Guido Tans

Jan Rosing

Jürgen Siekmann

The invention generally relates to methods of testing the effectiveness of a von Willebrand factor (VWF) in treating von Willebrand disease (VWD) in a subject comprising measuring VWF cleavage fragments in a blood sample from the subject before and after treatment. In particular, the invention relates to methods of measuring VWF cleavage fragments, wherein an increase in VWF cleavage fragments after the treatment indicates that endogenous a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13) in the subject is cleaving the VWF and wherein a decrease or absence of VWF cleavage fragments after the treatment indicates that endogenous ADAMTS13 in the subject is not cleaving the VWF.

Methods for testing effectiveness of a von Willebrand factor used in treating von Willebrand disease (VWD)

The invention generally relates to methods of measuring cleaved von Willebrand factor (VWF) fragments. More specifically, the invention relates to methods of measuring the ability of a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13) to cleave VWF in vivo. The invention also relates to methods of using various animal models which demonstrate ADAMTS13 activity similar to that of a human. The invention further relates to methods of measuring the cleavage products of rVWF in mammals, particularly in humans and in human plasma.

Methods of measuring adamts 13 activity

The present invention relates to a method for determining the amount of a physiologically acceptable polymer molecule bound to a protein, an antibody or other composition being capable of specifically binding to a physiologically acceptable polymer molecule, and a kit containing said antibody or composition.

Method and compositions for specifically detecting physiologically acceptable polymer molecules

The present invention provides von Willebrand Factor-polymer conjugates and Factor VIII-polymer conjugates, each having a releasable linkage. Methods of making conjugates, methods for administering conjugates, are also provided.

Von willebrand factor- and factor VIII-polymer conjugates having a releasable linkage

Methods of measuring ADAMTS 13 activity

The invention relates to the development of in vitro assay systems that force the release of a water-soluble polymer, such as polyethylene glycol (PEG) and polysialic acid (PSA), from proteins modified with a reversibly-linked water-soluble polymer. The invention includes methods for analyzing the release of the water-soluble polymer and measuring regained protein activity. The invention further includes methods appropriate for the quality control of proteins modified with releasable water-soluble polymers, including polymers like PEG and PSA.

Methods for determining active ingredients in pro-drug PEG protein conjugates with releasable PEG reagents (in vitro de-pegylation)

Methods of testing effectiveness of a treatment for thromobotic thrombocytopenic purpura by measuring ADAMTS13-mediated in vivo cleavage of von Willebrand factor

The invention provides a kit for measuring the thrombin generation in a sample of a patient's blood or plasma, or in a sample of clotting factors. The kit contains lyophilized tissue factor/phospholipid-complex and a lyophilized mixture containing a thrombin-substrate and CaCl. The invention also provides processes for preparing the reagents for the kit. The kit can be used in a method for measuring the thrombin generation in a sample, wherein it is possible to detect changes in thrombin generation kinetics, for example after administration of inhibitor bypassing agents to a patient who has developed inhibitors to an exogenous clotting factor such as Factor VIII.

Kit for measuring the thrombin generation in a sample of a patient's blood or plasma

Method for testing treatment of ADAMTS13 deficiency

Methods of measuring ADAMTS13-mediated in vivo cleavage of von Willebrand factor and uses thereof

Von Willebrand factor- and factor VIII-polymer conjugates having a releasable linkage

von Willebrand factor- and factor VIII-polymer conjugates having a releasable linkage

The invention is a proteinaceous construct comprising a Factor VIII molecule having at least a portion of the B domain intact, which is conjugated to a water-soluble polymer such as polyethylene glycol having a molecular weight of greater than 10,000 Daltons. The construct has a biological activity of at least 80% of the biological activity of native Factor VIII, and the in vivo half-life of the construct is increased by at least 1.5 fold as compared to the in vivo half-life of native factor FVIII.

Pegylated factor VIII

Growing community of inventors

Vienna, Austria

Katalin Varadi